CDK 抑制改善高危激素受体阳性乳腺癌的结局。

1

J Clin Oncol. 2022 Apr 10;40(11):1142-1146. doi: 10.1200/JCO.21.02850. Epub 2022 Feb 24.

2

J Clin Oncol. 2022 May 1;40(13):1400-1406. doi: 10.1200/JCO.22.00167. Epub 2022 Mar 3.

3

J Clin Oncol. 2024 Oct 20;42(30):3517-3522. doi: 10.1200/JCO-24-01352. Epub 2024 Sep 20.

4

J Clin Oncol. 2020 Apr 20;38(12):1258-1267. doi: 10.1200/JCO.19.02242. Epub 2019 Oct 16.

5

J Clin Oncol. 2022 May 20;40(15):1604-1610. doi: 10.1200/JCO.22.00049. Epub 2022 Feb 28.

6

J Clin Oncol. 2022 Mar 20;40(9):927-931. doi: 10.1200/JCO.21.02706. Epub 2022 Feb 4.

7

J Clin Oncol. 2020 Jul 10;38(20):2290-2298. doi: 10.1200/JCO.19.03036. Epub 2020 May 22.

8

J Clin Oncol. 2024 Dec;42(34):4012-4017. doi: 10.1200/JCO-24-01295. Epub 2024 Sep 18.

9

J Clin Oncol. 2025 Jan;43(1):4-9. doi: 10.1200/JCO.24.00757. Epub 2024 Sep 3.

10

J Clin Oncol. 2020 Nov 20;38(33):3833-3840. doi: 10.1200/JCO.20.01641. Epub 2020 Jul 24.

Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.